President-elect Donald Trump this week nominated Robert F. Kennedy Jr. to be the next Secretary of ... [+] the U.S. Department of Health and Human Services. In this photo, the vaccine skeptic speaks during a hearing with the House Judiciary Subcommittee on the Weaponization of the Federal Government on Capitol Hill on July 20, 2023 in Washington, DC. (Photo by Anna Moneymaker/Getty Images)Getty ImagesStocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Do ...

GSK plc (NYSE:GSK) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez I'm absolutely thrilled that this we're clearly going to have the best conversation in the fireside chat that we've had so far. Incredibly pleased to have Emma Walmsley here. She's CEO and on the Board of Directors of GlaxoSmithKline, or sorry, GSK. I have to, I can't s ...

GSK plc (NYSE:GSK) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez I'm absolutely thrilled that this we're clearly going to have the best conversation in the fireside chat that we've had so far. Incredibly pleased to have Emma Walmsley here. She's CEO and on the Board of Directors of GlaxoSmithKline, or sorry, GSK. I have to, I can't s ...

GSK plc (GSK) reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a reported basis but rose 5% at a constant exchange rate (CER). Quarterly revenues fell 2% on a reported basis but rose 2% at CER to $10.42 billion (£8.01 billion). The top line missed the Zacks Consensus Estimate of $10.65 billion. This was due to lower sales of RSV and shingles vaccines in the United States. All ...

30 October 2024 Q3 2024 Results Conference call and webcast for investors and analysts gsk.com Cautionary statement regarding forward-looking statements 2 This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'projec ...

GSK plc (NYSE:GSK) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Jeff McLaughlin - IR Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JPMorgan Kerry Holford - Berenberg Jo Walton - UBS Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Richard Parkes - BNP Paribas Peter Welford ...

GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 9.48%. A quarter ago, it was expected that this drug developer would post earnings of $1 per share when it actually produced earnings of $1.09, delivering a surprise of 9%. Over the last four quarters, the company has surpassed ...

British pharmaceutical company GSK (NYSE: GSK ) reported its third quarter (Q3 2024) and nine months 2024 (9m 2024) results earlier today, which indicate that it's on track to achieve the full-year targets. This is even as Q3 2024 figures showed softening. Here, I Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gree ...

KEY TAKEAWAYS GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lowerthan-estimated quarterly sales and lowered its projection for vaccine sales. The company reported third-quarter sales of 8.01 billion pounds ($9.59 billion), down 2% year-over-year on lower vaccine sales and below consensus estimates of analysts polled by Visible Alpha of 8.09 billion pounds. The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease ...

-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of nonadjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while demonstrating significantly better tolerability compared to AREXVY -- -- Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 in an RSV re-vaccination setting and as part of a respiratory combination va ...